Cardiff Oncology, Inc.
NASDAQ:CRDFBiotechnology
Healthcare
$0.84 +2.12%
+$0.03 today
- Market cap
- $65.27M
- Beta
- 1.38
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$0.65
52W Low $1.16High $4.56
Volume 0.86M
Average 1.05M
Income Statement
Follow revenue through to earnings.
Revenue
$593,000.00
FY 2025 · Annual
-13.2% YoYOperating Income
-$48.96M
FY 2025 · Annual
Net Income
-$45.85M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 359K | 386K | 488K | 683K | 593K |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 359K | 386K | 488K | 683K | 593K |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 17.38M | 27.11M | 32.86M | 36.85M | 35.33M |
| Selling, General & Admin | 11.84M | 13.18M | 13.04M | 12.48M | 14.22M |
| Operating Expenses | 29.21M | 40.29M | 45.9M | 49.33M | 49.55M |
| Depreciation & Amortization | 451K | 236K | 398K | 404K | 904K |
| EBITDA | (27.84M) | (38.47M) | (41.04M) | (45.03M) | (44.95M) |
| EBITDA Margin | -7754.9% | -9965.8% | -8410.5% | -6592.5% | -7579.6% |
| Operating Income | (28.86M) | (39.9M) | (45.41M) | (48.65M) | (48.96M) |
| Operating Margin | -8037.6% | -10337.3% | -9305.7% | -7123.1% | -8256.3% |
| Interest Income | 264K | 1.58M | 4.07M | 3.26M | 3.1M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 564K | 1.2M | 3.97M | 3.22M | 3.11M |
| Income Before Tax | (28.29M) | (38.7M) | (41.44M) | (45.43M) | (45.85M) |
| Pre-Tax Margin | -7880.5% | -10026.9% | -8492.0% | -6651.7% | -7732.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (28.29M) | (38.7M) | (41.44M) | (45.43M) | (45.85M) |
| Net Margin | -7880.5% | -10026.9% | -8492.0% | -6651.7% | -7732.0% |
| EPS (Basic) | (0.73) | (0.89) | (0.93) | (0.95) | (0.69) |
| EPS (Diluted) | (0.73) | (0.89) | (0.93) | (0.95) | (0.69) |
| 39.03M | 43.6M | 44.68M | 47.65M | 66.84M | |
| 39.03M | 43.6M | 44.68M | 47.65M | 66.84M |
CRDF Earnings Waterfall · TTM
NASDAQ:CRDF · Revenue to Net Income
Key Ratios
EPS$-0.67
Gross Margin-2292.6%
Net Margin-13496.0%
P/E Ratio-3.9
P/S Ratio1588.4
Analysis
$525.0K of revenue converted into -$44.8M of net income for the selected period. Gross margin is -2292.6% and net margin is -13496.0%, showing how much revenue survives after costs and taxes. EPS is $-0.67, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 12, 2026 | |
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 3 | Initial statement of beneficial ownership | Oct 27, 2026 | |
| 8-K | Current report | Oct 27, 2026 | |
| 8-K | Current report | Oct 22, 2026 |
How much revenue does CRDF generate?
Cardiff Oncology, Inc. (CRDF) reported $593,000.00 of revenue in fiscal 2025.
Is CRDF profitable?
Cardiff Oncology, Inc. (CRDF) reported -$45.85M of net income, with a net margin of -7732.0%.
Continue the stock analysis
Jump to another research area for this company.